Table 1.
List of circRNAs reported as potential biomarkers in breast cancer.
| circRNA | circBase ID | Tissue Comparison |
Expression in T | Clinical Interest | Diagnostic/Prognostic Value (ROC/KM Curve) | Experimental Approach |
|---|---|---|---|---|---|---|
| circABCB10 | hsa_circ_008717 | T vs. N | up | diagnosis | - | ex vivo, in vitro, in silico [51] |
| circDENND4C | - | diagnosis, prognosis | - | ex vivo, in vitro, in vivo, in silico [52,53] | ||
| circHIPK3 | hsa_circ_0000284 | diagnosis, prognosis | - | ex vivo, in vitro, in vivo, in silico [54,55,56] | ||
| circHMCU | hsa_circ_0000247 | diagnosis, prognosis | HR = 3.09, p = 0.039 | ex vivo, in vitro, in vivo, in silico [57] | ||
| circPTCD3 | hsa_circ_0055478 | diagnosis | - | ex vivo, in vitro, in vivo [58] | ||
| cirRNF20 | hsa_circ_0087784 | diagnosis, prognosis | - | ex vivo, in vitro, in vivo [59] | ||
| circRPPH1_015 | hsa_circ_0000517 | diagnosis, prognosis | - | ex vivo, in vitro, in vivo, in silico [60] | ||
| - | hsa_circ_0001791 | early stage diagnosis | AUC = 1.0, p < 0.0001 | ex vivo, in silico [61] | ||
| - | hsa_circ_0002496 | early stage diagnosis | - | ex vivo, in silico [62] | ||
| - | hsa_circ_0005046 | early stage diagnosis | AUC = 0.77, p = 0.02 | ex vivo, in silico [61] | ||
| - | hsa_circ_0005230 | diagnosis, prognosis | HR = 1.945, p = 0.042 | ex vivo, in vitro, in silico [63] | ||
| - | hsa_circ_0006743 | early stage diagnosis | - | ex vivo, in silico [62] | ||
| - | hsa_circ_103110 | diagnosis | AUC = 0.63, p = 0.016 | ex vivo, in silico [64] | ||
| - | hsa_circ_103552 | diagnosis, prognosis | - | ex vivo, in vitro, in silico [65] | ||
| - | hsa_circ_104689 | diagnosis | AUC = 0.61, p = 0.041 | ex vivo, in silico [64] | ||
| - | hsa_circ_104821 | diagnosis | AUC = 0.60, p = 0.031 | ex vivo, in silico [64] | ||
| circCCDC85A | down | diagnosis | - | ex vivo, in vitro, in vivo, in silico [66] | ||
| circLARP4 | - | diagnosis, prognosis | - | ex vivo, in vitro, in silico [67] | ||
| circVRK1 | hsa_circ_0141206 | diagnosis, prognosis | AUC = 0.720, Sensitivity = 61.7%, Specificity = 79.1%, HR = 0.375, p = 0.002 | ex vivo, in vitro, in silico [68] | ||
| - | hsa_circ_006054 | diagnosis | AUC = 0.71, p < 0.001 | ex vivo, in silico [64] | ||
| - | hsa_circ_0072309 | diagnosis, prognosis | - | ex vivo, in vitro, in vivo, in silico [69] | ||
| - | hsa_circ_100219 | diagnosis | AUC = 0.78, p < 0.001 | ex vivo, in silico [64] | ||
| - | hsa_circ_406697 | diagnosis | AUC = 0.64, p < 0.008 | ex vivo, in silico [64] | ||
| circRNA | circBase ID |
Tissue
comparison |
Expression in TNBC | Clinical interest | Diagnostic/prognostic value (ROC/KM curve) | Experimental approach |
| circAGFG1 | - | TNBC vs. N | up | diagnosis, prognosis | AUC = 0.767, HR = 6.072, p < 0.001 | ex vivo, in vitro, in vivo, in silico [70] |
| circEPSTI1 | - | - | ex vivo, in vitro, in vivo, in silico [71] | |||
| circFBXW7 | hsa_circ_0001451 | HR = 0.215, p = 0.001 | ex vivo, in vitro, in vivo, in silico [72] | |||
| circGFRA1 | hsa_circ_005239 | - | ex vivo, in vitro, in vivo, in silico [73,74] | |||
| circKIF4A | - | - | ex vivo, in vitro, in vivo, in silico [75] | |||
| circPDCD11 | hsa_circ_0019853 | - | ex vivo, in vitro, in vivo, in silico [76] | |||
| circSEPT9 | hsa_circ_0005320 | AUC = 0.711, Specificity = 75%, Sensitivity = 63.3%, HR = 3.042, p = 0.012 | ex vivo, in vitro, in vivo, in silico [77] | |||
| circUBAP2 | hsa_circ_0001846 | - | ex vivo, in vitro, in vivo, in silico [78] | |||
| circUBE2D2 | hsa_circ_0005728 | - | ex vivo, in vitro, in vivo, in silico [79] | |||
| circTADA2A-E6 | hsa_circ_0006220 | down | AUC = 0.855, p < 0.0001 | ex vivo, in vitro, in vivo, in silico [80] | ||
| circTADA2A-E5/E6 | hsa_circ_0043278 | AUC = 0.94, p < 0.001 | ex vivo, in vitro, in vivo, in silico [80] | |||
| circRNA | circBase ID | Cell line comparison | Expression in TNBC | Clinical interest | Diagnostic/prognostic value (ROC/KM curve) | Experimental approach |
| circSLC8A1 | - | TNBC vs. luminal | up | diagnosis, BC subtypedistinction | - | ex vivo, in vitro, in vivo, in silico [81] |
| - | hsa_circ_001783 | TNBC vs. luminal/HER2 | diagnosis, prognosis | HR = 9.114, p = 0.001 | ex vivo, in vitro, in silico [82] | |
| circASS1 | hsa_circ_0089105 | TNBC vs. luminal | down | diagnosis | - | in vitro, in silico [83] |
| circNR3C2 | hsa_circ_0071127 | TNBC vs. luminal | diagnosis, prognosis | - | ex vivo, in vitro, in vivo, in silico [84] | |
| - | hsa_circ_0044234 | TNBC vs. non-TNBC | diagnosis, BC subtype distinction | AUC = 0.82, p < 0.0001, Sensitivity = 72.5%, Specificity = 83.6%, HR = 0.47, p = 0.058 | ex vivo, in vitro, in silico [85] | |
| circRNA | circBase ID |
Cell line
comparison |
Expression in luminal/epithelial TNBC | Clinical interest | Diagnostic/prognostic value (ROC/KM curve) | Experimental approach |
| circDOCK1-1 | hsa_circ_0020397 | luminal/epithelial TNBC vs. mesenchymal TNBC cell lines | up | diagnosis, BC subtype distinction | - | in vitro, in silico [86] |
Abbreviations: AUC, area under the curve; BC, breast cancer; circRNAs, circular RNAs; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; N, normal breast tissue; ROC, receiver operating characteristic; T, breast tumor tissue; TNBC, triple-negative breast cancer.